Literature DB >> 15821958

Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.

Anil Purohit1, Carol Smith, Katharine Herrick-Davis, Milt Teitler.   

Abstract

RATIONALE: In order to determine the possible relationship between antipsychotic drug properties and inverse agonist activity at h5HT6 and h5HT7 receptors, constitutively activated forms of these receptors were created by site-specific mutagenesis. Typical and atypical antipsychotic drugs were assayed for their potencies as inverse agonists at these mutated receptors.
OBJECTIVES: Stable cell lines expressing constitutively activated forms of the h5HT6 and h5HT7 receptors were created. Typical and atypical antipsychotic drugs demonstrating high to moderate affinities for the h5HT6 and h5HT7 receptors were assayed for their potencies in reversing the agonist-independent activity (inverse agonist activity).
RESULTS: The E322R h5HT6 mutant and the S267K h5HT7 mutant displayed sufficiently robust agonist-independent activity when expressed in stable cell lines to allow the detailed, concentration-dependent, investigation of the inverse agonist activity of typical and atypical antipsychotic drugs. All the drugs tested displayed inverse agonist activity at both the activated h5HT6 and h5HT7 receptors. Native forms of these receptors did not display any constitutive activity. Interestingly, atypical antipsychotic drugs displayed potent inverse agonist activity, relative to typical antipsychotic drugs, at the h5HT7 receptor. LSD displayed neutral antagonist properties at the mutant h5HT7 receptor.
CONCLUSIONS: Site-specific mutations in the third intracellular loop of the G(s)-coupled h5HT6 and h5HT7 receptors produce constitutive activation. Antipsychotic drugs display inverse agonist activity at the activated receptors. The inverse agonist mechanism-of-action of the atypical antipsychotic drugs at the h5HT7 receptors may be different from the typical antipsychotic drugs as these drugs displayed far higher potencies as inverse agonists at the h5HT7 receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15821958     DOI: 10.1007/s00213-004-2057-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.

Authors:  C Egan; E Grinde; A Dupre; B L Roth; M Hake; M Teitler; K Herrick-Davis
Journal:  Synapse       Date:  2000-02       Impact factor: 2.562

2.  RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity.

Authors:  C M Niswender; S C Copeland; K Herrick-Davis; R B Emeson; E Sanders-Bush
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

3.  Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.

Authors:  R Kohen; M A Metcalf; N Khan; T Druck; K Huebner; J E Lachowicz; H Y Meltzer; D R Sibley; B L Roth; M W Hamblin
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

4.  Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.

Authors:  L Rauser; J E Savage; H Y Meltzer; B L Roth
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

5.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Authors:  A W Schmidt; L A Lebel; H R Howard; S H Zorn
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

Review 6.  Update on the clinical efficacy and side effects of clozapine.

Authors:  A Safferman; J A Lieberman; J M Kane; S Szymanski; B Kinon
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

7.  Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.

Authors:  Anil Purohit; Katharine Herrick-Davis; Milt Teitler
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

8.  Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.

Authors:  B L Roth; R D Ciaranello; H Y Meltzer
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

9.  Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor.

Authors:  K Herrick-Davis; E Grinde; C Gauthier; M Teitler
Journal:  Ann N Y Acad Sci       Date:  1998-12-15       Impact factor: 5.691

10.  Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors.

Authors:  G Battaglia; M Shannon; M Titeler
Journal:  J Neurochem       Date:  1984-11       Impact factor: 5.372

View more
  11 in total

1.  Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

2.  Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

Authors:  Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-05       Impact factor: 3.000

Review 3.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

4.  Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists.

Authors:  Gonzalo Romero; Marta Pujol; Petrus J Pauwels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-12       Impact factor: 3.000

5.  Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions.

Authors:  Milt Teitler; Nicole Toohey; Jessica A Knight; Michael T Klein; Carol Smith
Journal:  Psychopharmacology (Berl)       Date:  2010-09-09       Impact factor: 4.530

6.  Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways.

Authors:  Gonzalo Romero; Elisabeth Sánchez; Marta Pujol; Pilar Pérez; Xavier Codony; Jörg Holenz; Helmut Buschmann; Petrus J Pauwels
Journal:  Br J Pharmacol       Date:  2006-07-24       Impact factor: 8.739

7.  Is the 5-hydroxytryptamine 7 Receptor Constitutively Active in the Vasculature? A Study in Veins/Vein.

Authors:  Stephanie W Watts; Emma D Flood; Janice M Thompson
Journal:  J Cardiovasc Pharmacol       Date:  2022-08-01       Impact factor: 3.271

8.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

9.  Inverse agonism and its therapeutic significance.

Authors:  Gurudas Khilnani; Ajeet Kumar Khilnani
Journal:  Indian J Pharmacol       Date:  2011-09       Impact factor: 1.200

10.  5-HT7 Receptor Restrains 5-HT-induced 5-HT2A Mediated Contraction in the Isolated Abdominal Vena Cava.

Authors:  Romina Gonzalez-Pons; Kiera McRae; Janice M Thompson; Stephanie W Watts
Journal:  J Cardiovasc Pharmacol       Date:  2021-08-01       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.